A Disabled Woman Wanted to Starve Herself to Death. The State Wouldn't Let Her. A New Doc Looks at Her Case (Exclusive)
Director Reid Davenport's new documentary Life After examines the right-to-die question through the experiences of disabled people
Reid, who has cerebral palsy, uses the case of Elizabeth Bouvia, a young woman with cerebral palsy, as the centerpiece of the film
Bouvia was denied the right to starve herself in 1983Allowing a person with a dire health diagnosis or an unbearable level of pain to die might seem like an act of mercy to some people.
But what would happen if the government were to decide that anyone with a disability deserves the right to die? Filmmaker Reid Davenport confronts this question in his new documentary Life After, primarily through the story of Elizabeth Bouvia, a California woman with cerebral palsy who, at the age of 26, sought the legal right to starve herself to death.
This was in 1983, and some TV news broadcasts questioned why someone who was young and beautiful would want to end her life. She said she wanted to die because she hadn't been given the right to live in a society with a healthcare structure that valued the bottom line over her well-being.
Davenport, who also has cerebral palsy, and his producing partner at Multitude Films, Colleen Cassingham, kept hearing similar reasoning while making Life After, which is now playing in select theaters.
Bouvia articulated her argument well when her case moved to court — she was in pain, tired and bogged down by bureaucracy — but the state eventually sided with the hospital, which said it could not betray its oath to first do no harm. So what happened to this so-called pioneer in the right-to-die movement after the case ended?
That is the question Davenport set out to answer when he started working on Life After. Framed by Bouvia's story, the documentary explores expanded Canadian policies that allow nearly anyone with a disability to apply to die, why some disabled people have made the tough choice to die and how advocates for MAiD (medical aid in dying) defend the expansion of the policies from people with a terminal diagnosis to anyone with a disability.
The film amplifies varied voices and points of view, like Melissa Hickson, who says her husband Michael Hickson was denied lifesaving care because doctors decided his quality of life was too low, and Catherine Frazee, a professor who posits that you cannot address human suffering by killing people. One participant, Michal Kaliszan, details how he considered assisted dying after his mother, who was his primary caretaker, died, and he could no longer afford the care he needed.
While working on the documentary, Cassingham had to navigate a shift in taking right-to-die activism at face value as progressivism to fully understanding the implications of applying it to all disabled people.
"I thought assisted dying was really about personal choice and bodily autonomy, values that I'm deeply committed to," she tells PEOPLE. "And in learning from Reid and in working on this film, I realized there's so much more to the picture of how it actually works in society, and it's deeply linked with the ways that we do and don't value certain lives, and a deep-seated ableism that underpins so much of society."
Over the course of Life After, as Davenport searches for Bouvia's family and seeks to find out if she is still living, two themes emerge: that the focus on right-to-die policies ignores that so many disabled people are not given the right to live and that any one person deciding what a good quality of life is for someone else can be tricky.
"The themes at the heart of this film are not niche; they're not particular to the disability community. Things like healthcare, isolation and the way that we value other human lives are universal," Cassingham says. "Everyone has a stake in the fight for a society that is invested in care and in upholding each other's dignity in the systems that we build and live within."
Eventually, Davenport locates Bouvia's sisters, Teresa and Rebecca, and convinces them to appear on camera to talk about their sibling, who died in 2014. Encouraging the pair to open up about Bouvia was not easy, but Davenport's authenticity and transparency helped win them over.
"Their main concern was that Elizabeth's reputation and decisions were going to be questioned again, and we ensured that was not our intention," Davenport says. "Basically, trying to, with the audience, meet them where they were at, and not force them."
As Teresa and Rebecca share stories of Bouvia's life after the 1980s while the film visits people who have used or are considering using MAiD, it becomes clear that assisted dying may have its place in the medical system. However, as Davenport sees it, discussions about it should be handled carefully when the focus is on people with disabilities.
"We should be asking, 'How can we enable disabled people to live?' And support them, and allow them opportunities," he says. "There's this sinister perspective that we are a burden, that we suck up money. So there's this underlying incentive for the health industry to allow people to choose assisted suicide."
He continues, "What I would encourage people to do is to look at how we can better the lives of people with disabilities rather than leave them to die."
Near the end of the film, Davenport fills out the application for Canada's MAiD program to see how easy or hard it would be for him to qualify. What starts as a funny exercise becomes scary when he passes with flying colors. He reflects on this and on all the people he has met who have gone down the same path and says he can't imagine how different he would feel about his life without the support, care and passion he has.
In one particularly poignant moment, Cassingham agrees that her quality of life would also be greatly reduced without these things, but because she doesn't have a disability, she wouldn't be given the option to die because of it.
"Quality of life doesn't have much to do with the abilities of our bodies. When someone becomes disabled or is aging, there's a real grappling with what that means, because society has told us that what makes us productive and able to enjoy life revolves around our bodies and our ability to do certain things," she says. "But for me, I've experienced a real reframing of disability as a natural part of the fabric of human experience."
"I'm learning that quality of life resides somewhere else, and it involves the people around you, it involves being loved, and giving love and care," Cassingham adds. "And those are things we all have access to if we live in a society where care is fostered and relationships and interdependency is valued and fostered."
While Bouvia's life after her landmark court case quickly fell out of the news cycle, Davenport's film reappraises the right-to-die question — through the sweet recollections of Bouvia's sisters, home video footage and the context of many others who are choosing to die or questioning why it is even an option.
Life After is now playing in select theaters
Read the original article on People
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Teething 9-Month-Old Has Strange Bump in His Mouth. Docs Think It's a Tumor Until They See a Toy Embedded in His Gums
Rowan Steiner says 5 doctors examined the blue mass in her son's mouth before a specialist used a dental tool to pry it off A mom was changing her baby's diaper when she saw something that scared her. Rowan Steiner, 31, said her son, Max, then 9 months, was crying during the diaper change — and that's when she spotted a massive blue lump by his gums. The Salt Lake City, Utah, mom of five said she and her husband rushed her son to the hospital, where he spent 12 hours being examined by five different doctors, according to Daily Mail. Kennedy News & Media Part of a fidget toy that was in 9-month-old Max Steiner's mouth The PEOPLE App is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! Docs originally thought it was a tumor but admitted it could be something else. ADVERTISEMENT 'Throughout the day the doctors had mentioned it could be a toy. We were totally open to the idea because I have five children and a nine-month-old wants to put everything in their mouth at that stage,' Steiner said of the 2022 ordeal. But, 'I, his dad, and all of the doctors physically touched it ... every single person did.' One doctor even said Max needed a CT scan. But when an ear, nose, and throat specialist examined Max, he used a dental tool to pry the 'mass' off — and the Steiners discovered it was a bubble from a fidget toy that had come loose while the tot was sucking on it. Getty Stock image of a fidget toy. 'It was just suctioned so tightly that it wasn't moving at all,' Steiner told the outlet. 'We were like, 'How would this make sense?' A fidget toy was not what we were thinking of at all." 'We were terrified, and then when we found out it was a fidget toy, we were relieved.' ADVERTISEMENT Max had some swelling and bleeding around his gums after the plastic bubble was removed, but his mom shares, 'That was probably the best case scenario after thinking that it was going to be a tumor, or he could have swallowed it or choked on it.' Never miss a story — sign up for PEOPLE's free daily newsletter to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Read the original article on People


New York Times
20 minutes ago
- New York Times
Oxygen Machine Played Role in Fire That Killed 10 in Massachusetts, Officials Say
A fire that killed 10 people at an assisted living center in Fall River, Mass., this month began in a resident's second-floor room, where investigators found an oxygen machine and 'smoking materials,' officials said Tuesday. The presence of medical oxygen 'played a significant role' in the rapid start and spread of the fire on July 13 at the facility, Gabriel House, Jon Davine, the Massachusetts state fire marshal, said at a news conference. 'Smoking is especially dangerous when home oxygen is in use,' Mr. Davine said. 'No one should smoke around medical oxygen.' Officials said the fire was accidental. Thomas M. Quinn III, the district attorney for Bristol County, said that a preliminary examination of the scene and initial interviews, as well as additional evidence gathered in the last week, show that 'the fire did not appear to be set intentionally.' Investigators determined the fire began in a resident's room on the left side of the facility's second floor, Mr. Davine said. There were no signs that the fire was caused by cooking, lighting, heating, electrical outlets or appliances in the room, or by candles or incense, he said. But investigators found an oxygen concentrator — a medical device that filters oxygen from the air — and 'numerous smoking materials,' in the room, Mr. Davine said. An electrical or mechanical failure involving the oxygen concentrator, or the improper use or disposal of smoking materials, were identified as the two possible causes of the fire, Mr. Davine said. Want all of The Times? Subscribe.
Yahoo
an hour ago
- Yahoo
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences
Eupraxia's EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: . Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas. Story Continues Notice Regarding Forward-looking Statements and Information This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "suggests", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the expected enrollment and number of sites for the Phase 2b portion of the RESOLVE study; the expected parameters of the RESOLVE study; the availability of topline data and release of additional long-term data with higher doses and timing thereof; the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the expectations around proceeding to clinical trials for the Company's product candidates; the results gathered from studies and trials of Eupraxia's product candidates; the potential for the Company's technology to impact the drug delivery process; potential market opportunity for the Company's product candidates; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company's active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ ( and EDGAR ( Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise. For investor and media inquiries, please contact: Danielle Egan, Eupraxia Pharmaceuticals Inc. 778.401.3302 degan@ or Kevin Gardner, on behalf of: Eupraxia Pharmaceuticals Inc. 617.283.2856 kgardner@ SOURCE Eupraxia Pharmaceuticals Inc.